NASDAQ:KNSA

Kiniksa Pharmaceuticals . Class A Stock Insider Trading

Healthcare > Biotechnology

Buy KNSA

*Your capital is at risk

$47.85

+0.93 (+1.98%)

At Close: Jun 03, 2026

Kiniksa Pharmaceuticals . Class A Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.00. In total, the insiders bought 2.75M and sold 1.56M KNSA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.00
● Buy	2.75M shares
● Sell	1.56M shares
76% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 28, 2026 Buy	Share Option M-Exempt	Quart Barry D Director	Director	13 099 Value: $187.7K
Apr 28, 2026 Buy	Class A Ordinary Share M-Exempt	Quart Barry D Director	Director	13 099 Value: $187.7K
Apr 09, 2026 Sell	Class A Ordinary Share S-Sale	Moat Ross Chief Operating Officer	C-Suite Officer	1 703 Value: $79.5K
Apr 09, 2026 Sell	Class A Ordinary Share S-Sale	Megna Michael R Chief Accounting Officer	Officer	6 625 Value: $309.3K
Apr 07, 2026 Sell	Class A Ordinary Share F-InKind	Moat Ross Chief Operating Officer	C-Suite Officer	774 Value: $37.9K
Apr 07, 2026 Buy	Restricted Share Unit M-Exempt	Moat Ross Chief Operating Officer	C-Suite Officer	2 477 Value: $121.2K
Apr 07, 2026 Buy	Class A Ordinary Share M-Exempt	Megna Michael R Chief Accounting Officer	Officer	3 932 Value: $4K
Apr 07, 2026 Sell	Class A Ordinary Share F-InKind	Megna Michael R Chief Accounting Officer	Officer	1 666 Value: $81.5K
Apr 07, 2026 Buy	Restricted Share Unit M-Exempt	Megna Michael R Chief Accounting Officer	Officer	3 932 Value: $192.4K
Apr 07, 2026 Buy	Class A Ordinary Share M-Exempt	Tessari Eben Chief Strategy Officer	Officer	2 726 Value: $133.4K
Apr 07, 2026 Buy	Class A Ordinary Share M-Exempt	Ragosa Mark Chief Financial Officer	C-Suite Officer	2 694 Value: $131.8K
Apr 07, 2026 Buy	Restricted Share Unit M-Exempt	Tessari Eben Chief Strategy Officer	Officer	2 726 Value: $133.4K
Apr 07, 2026 Sell	Class A Ordinary Share F-InKind	Patel Sanj K Chairman & CEO	CEO / President	4 831 Value: $236.4K
Apr 07, 2026 Buy	Restricted Share Unit M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	9 991 Value: $489.0K
Apr 07, 2026 Buy	Class A Ordinary Share M-Exempt	Moat Ross Chief Operating Officer	C-Suite Officer	2 477 Value: $121.2K
Apr 07, 2026 Buy	Restricted Share Unit M-Exempt	Paolini John F. Chief Medical Officer	Officer	2 497 Value: $122.2K
Apr 07, 2026 Sell	Class A Ordinary Share F-InKind	Paolini John F. Chief Medical Officer	Officer	1 208 Value: $59.1K
Apr 07, 2026 Buy	Class A Ordinary Share M-Exempt	Paolini John F. Chief Medical Officer	Officer	2 497 Value: $122.2K
Apr 07, 2026 Buy	Restricted Share Unit M-Exempt	Ragosa Mark Chief Financial Officer	C-Suite Officer	2 694 Value: $131.8K
Apr 07, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	9 991 Value: $489.0K
Apr 07, 2026 Sell	Class A Ordinary Share F-InKind	Tessari Eben Chief Strategy Officer	Officer	846 Value: $41.4K
Apr 07, 2026 Sell	Class A Ordinary Share F-InKind	Ragosa Mark Chief Financial Officer	C-Suite Officer	1 303 Value: $63.8K
Apr 06, 2026 Sell	Class A Ordinary Share S-Sale	Moat Ross Chief Operating Officer	C-Suite Officer	2 367 Value: $115.0K
Apr 06, 2026 Buy	Share Option M-Exempt	Quart Barry D Director	Director	6 901 Value: $98.9K
Apr 06, 2026 Sell	Class A Ordinary Share S-Sale	Quart Barry D Director	Director	6 901 Value: $345.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KINIKSA PHARMACEUTICALS LTD. CLASS A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

Read Full Profile Here